Phase III Insulin Add-On Asia Regional Program - ST
A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100039
- Local Institution
-
Tianjin, China
- Local Institution
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Local Institution
-
Beijing, Beijing, China, 100029
- Local Institution
-
Beijing, Beijing, China, 100700
- Local Institution
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Local Institution
-
Guangzhou, Guangdong, China, 510120
- Local Institution
-
-
Heilongjiang
-
Haerbin, Heilongjiang, China, 150001
- Local Institution
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Local Institution
-
Changsha, Hunan, China, 410000
- Local Institution
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210012
- Local Institution
-
Suzhou, Jiangsu, China, 215004
- Local Institution
-
Wuxi, Jiangsu, China, 214023
- Local Institution
-
-
Jilin
-
Changchun, Jilin, China, 130041
- Local Institution
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Local Institution
-
Shanghai, Shanghai, China, 200040
- Local Institution
-
Shanghai, Shanghai, China, 200072
- Local Institution
-
Shanghai, Shanghai, China, 200092
- Local Institution
-
-
Shanxi
-
Xi An, Shanxi, China, 710032
- Local Institution
-
Xi'an, Shanxi, China, 710061
- Local Institution
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Local Institution
-
Chongqing, Sichuan, China, 400010
- Local Institution
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Local Institution
-
Daegu, Korea, Republic of, 42415
- Local Institution
-
Daejeon, Korea, Republic of, 35233
- Local Institution
-
Seoul, Korea, Republic of, 06351
- Local Institution
-
Seoul, Korea, Republic of, 134-727
- Local Institution
-
-
-
-
-
Singapore, Singapore, 169856
- Local Institution
-
Singapore, Singapore, 529889
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit
- Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment
Inclusion criteria for randomization:
HbA1c ≥ 7.5 and ≤ 10.5% at Day -14
Exclusion Criteria:
- Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment
- History of diabetic ketoacidosis of hyperosmolar nonketotic coma
- Clinically diagnosed Type 1 diabetes mellitus
- Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV
- Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg
- History of unstable or rapidly progressing renal disease
- History of severe hepatobiliary disease
- Mallingancy within 5 years of the screening/enrollment visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group 1: Dapagliflozin
Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
|
Tablet
Other Names:
|
|
Placebo Comparator: Group 2: Dapagliflozin Placebo
Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
|
Tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adjusted Mean Change in HbA1c From Baseline to Week 24
Time Frame: Baseline (Day 1) and 24 weeks
|
The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.
|
Baseline (Day 1) and 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24
Time Frame: Baseline (Day 1) and 24 weeks
|
The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).
|
Baseline (Day 1) and 24 weeks
|
|
Adjusted Mean Change in Body Weight From Baseline to Week 24
Time Frame: Baseline (Day 1) and 24 weeks
|
Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).
|
Baseline (Day 1) and 24 weeks
|
|
Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24
Time Frame: Baseline (Day 1) and 24 weeks
|
The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).
|
Baseline (Day 1) and 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MB102-137
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.